AstraZeneca Reports P-III (T2NOW) Trial Results of Forxiga (dapagliflozin) for Type 2 Diabetes
Shots:
- The positive results from the P-III trial evaluating dapagliflozin (sodium-glucose cotransporter 2 inhibitor) as an add-on treatment vs PBO in children & adolescents with T2D who received metformin, insulin, or both
- The results showed a significant reduction in A1C, mean change in A1C (−0.62% vs +0.41%), statistical significance was achieved in the 1EPs & 2EPs at 26wk., and improvements in glycemia for children & adolescent patients aged 10-17yrs. with T2D were also reported. The safety results were consistent with those in adults with T2D & with the well-established safety profile for Forxiga
- The results were presented at the 59th Annual Meeting of the EASD Congress & published in the NEJM. Forxiga was approved in 100+ countries globally for HFrEF & CKD
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca’s Forxiga (dapagliflozin) Receives the NMPA’s Approval for Adult Patients with Symptomatic Chronic Heart Failure
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
